Nasal Biomarkers of Acute Illness Severity and Predictors of Recurrent Wheeze in Infants Infected With Respiratory Syncytial Virus
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiag049 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Mary T Caserta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Sounds, Biomarkers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Merck Investigator Studies Program, Merck and Co, Inc.
Abstract (Originalsprache)
Background
Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants, and those with RSV disease appear more likely to develop recurrent wheeze. We examined nasal airway gene expression and microbiome composition during primary RSV infection to test associations with illness severity and identify infants with recurrent wheeze.
Methods
Previously healthy infants with RSV infection were enrolled (December 2019–December 2023). Clinical and demographic data were collected, as were 2 anterior nasal swabs and a nasal wash for metagenome and transcriptome sequencing. Disease severity was measured by the improved Global Respiratory Severity Score (iGRSS). Participants were followed for approximately 1 year to identify recurrent wheeze. Multivariate regression models were developed to identify correlates and predictors of disease severity and recurrent wheeze, respectively.
Results
One hundred infants (90 hospitalized) were enrolled (mean ± SD age, 3.2 ± 2.3 months; 61% male). An overall 405 genes (false discovery rate, 0.10) were significantly and consistently associated with illness severity (iGRSS), implicating innate immune and interleukin signaling pathways. The abundance of nasal Dolosigranulum was inversely associated with iGRSS, while the abundance of Haemophilus was directly associated with iGRSS. Predictive models based on nasal gene expression during infection had the power to classify recurrent wheeze (in-sample area under the curve, 0.992; cross-validated area under the curve, 0.882), while metagenomic features did not improve predictive performance.
Conclusions
We prospectively followed infants with primary RSV infection and identified associations among nasal gene expression, microbiome composition/function, and acute disease severity and recurrent wheeze. Host transcriptional profiles during infection were predictive of recurrent wheeze within the following year.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics.
- Department of Medicine.
- Department of Microbiology and Immunology.
- Clinical and Translational Science Institute.
- Department of Biostatistics and Computational Biology, University of Rochester Medical Center, NewYork.
ORCID-Profile: Mary T Caserta, Edward E Walsh, Ann L Gill, Xing Qiu
Förderung
- Merck Investigator Studies Program
- Merck and Co, Inc
Zitieren
APA
Caserta, M. T., Mariani, T. J., Walsh, E. E., Gill, S. R., Gill, A. L., Corbett, A., Harrington, D., Chu, C., & Qiu, X. (2026). Nasal Biomarkers of Acute Illness Severity and Predictors of Recurrent Wheeze in Infants Infected With Respiratory Syncytial Virus. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag049
Vancouver
Caserta MT, Mariani TJ, Walsh EE, Gill SR, Gill AL, Corbett A, et al. Nasal Biomarkers of Acute Illness Severity and Predictors of Recurrent Wheeze in Infants Infected With Respiratory Syncytial Virus. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag049
BibTeX
@article{Caserta2026,
author = {Caserta, Mary T and Mariani, Thomas J and Walsh, Edward E and Gill, Steven R and Gill, Ann L and Corbett, Anthony and Harrington, Donald and Chu, ChinYi and Qiu, Xing},
title = {Nasal Biomarkers of Acute Illness Severity and Predictors of Recurrent Wheeze in Infants Infected With Respiratory Syncytial Virus},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag049}
}
EUVIMED